OBJECTIVES: The purpose of this study was to investigate associations between use of @entity2162 ( @entity2162 ) agonist drugs during pregnancy and risk for @entity72 ( @entity72 ). METHODS: A case-control study was conducted by using Denmark's health and population registers. Among @entity1 born between 1997 and 2006, 5200 cases with @entity72 admission diagnoses and 52   000 controls without @entity72 were identified and individually matched on month and year of birth. Conditional logistic regression models were used to estimate odds ratios (OR) and confidence intervals (CI) for any @entity2162 agonist exposure during pregnancy, preconception, and by trimester. RESULTS: In total, 3.7% of cases and 2.9% of controls were exposed to B2ARs during pregnancy. Use of B2ARs during pregnancy was associated with increased risk of @entity72 , even after adjustment for maternal @entity565 and other covariates (OR: 1.3, 95% CI: 1.1-1.5). The elevated risk was observed with use of @entity2162 during preconception (OR: 1.3, 95% CI: 1.0-1.6), first trimester (OR: 1.3, 95% CI: 1.1-1.5), second trimester (OR: 1.5, 95% CI: 1.1-1.7), and the third trimester (OR: 1.4, 95% CI: 1.1-1.7). There was some evidence that longer @entity2162 within-pregnancy use was associated with the increased risk. CONCLUSIONS: @entity2162 agonist exposure during pregnancy may be associated with an increased risk for @entity72 . If the effect is real, any intervention must be balanced against benefits of indicated medication use by pregnant @entity1 .

In utero Exposure to XXXX Agonist Drugs and Risk for Autism Spectrum Disorders.

@entity1 :: ('9606', 'Species') :: ['women', 'children'] @entity565 :: ('MESH:D001249', 'Disease') :: ['asthma'] @entity2162 :: ('154', 'Gene') :: ['b-2-adrenergic receptor', 'B2AR'] @entity72 :: ('MESH:D002659', 'Disease') :: ['ASD', 'autism spectrum disorders']
@entity2162 :: (154,Gene) :: ['b-2-Adrenergic Receptor']
